IMMUNIC IMUX 深 沪
等待开盘 02-07 09:30:00 美东时间
0.6142
+0.025
+4.28%
华盛通- 最 高0.619
- 今 开0.5926
- 成交量 90.26万股
- 最 低 0.5801
- 昨 收 0.589
- 总市值 7387.89万
- 52周最高 1.39
- 市盈率 静 --
- 换手率 0.75%
- 52周最低 0.5062
- 委 比 60.78%
- 总股本 1.20亿
- 历史最高 28.99
- 量 比 1.03
- 振 幅 6.60%
- 历史最低 0.5062
- 每 手 1
- 风险率 0.18%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Immunic Unveils Positive Phase 2 CALLIPER Trial Data for Vidofludimus Calcium in Progressive Multiple Sclerosis
Immunic Unveils Positive Phase 2 CALLIPER Trial Data for Vidofludimus Calcium in Progressive Multiple Sclerosis Immunic Inc. has announced that it will present additional data from its phase 2 CALLIPER trial of vidofludimus calcium (IMU-838) in patients with progressive multiple sclerosis at the ACT
02-04 19:30
美股大行评级 | 瑞银上调美光科技目标价从300美元升至400美元；Freedom上调百度目标价从120美元升至160美元
今日重点评级关注：Needham：维持Vaxcyte"买入"评级，目标价从90美元升至110美元；Citizens: 维持LGI Homes"跑赢大市"评级，目标价从85美元升至95美元
01-08 18:33
D. Boral Capital Maintains Buy on Immunic, Maintains $8 Price Target
D. Boral Capital analyst Jason Kolbert maintains Immunic (NASDAQ:IMUX) with a Buy and maintains $8 price target.
01-07 21:57
Immunic Highlights 2025 Accomplishments and Upcoming Milestones
– Completed Enrollment for Both Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis; Top-Line Data Expected by End of 2026 – – Phase 2 CALLIPER Data Showed Vidoflud...
01-07 19:30
美股大行评级 | 花旗上调Bilibili目标价升至27美元； 摩根士丹利上调英伟达目标价升至220美元；Ardent Health、Stubhub遭多家大行下调评级
花旗上调Bilibili目标价升至27美元； 摩根士丹利上调英伟达目标价升至220美元；Ardent Health、Stubhub遭多家大行下调评级>>
2025-11-17 10:49
美股大行评级 | 思科、On Holding、派拓网络等获多家机构上调目标价；Circle 遭富国、德银等多家机构下调目标价
今日重点评级关注：HC Wainwright & Co.：维持PDS Biotechnology"买入"评级，目标价从13美元升至15美元；HC Wainwright & Co.：维持PepGen Inc."买入"评级，目标价从18美元升至20美元
2025-11-14 10:43
D. Boral Capital Maintains Buy on Immunic, Lowers Price Target to $8
D. Boral Capital analyst Jason Kolbert maintains Immunic (NASDAQ:IMUX) with a Buy and lowers the price target from $10 to $8.
2025-11-13 21:47
Immunic Q3 EPS $(0.13) Beats $(0.18) Estimate
Immunic (NASDAQ:IMUX) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.18) by 26.14 percent. This is a 45.83 percent increase over losses of $(0.24) per share from the same
2025-11-13 19:33
华尔街顶级分析师最新观点：Datadog、Trade Desk获上调
华尔街最受关注、且能影响市场走势的研究观点现已汇总于此。以下是由 The Fly 整理的今日投资者需关注的研究评级变动。 主要评级上调 KeyBanc：将...
2025-11-07 23:17
美股大行评级 | 潜在涨幅207.38%！GoldMining获HC Wainwright升目标价至3.75美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持GoldMining"买入"评级，目标价从3.25美元升至3.75美元；摩根士丹利：维持Crinetics Pharmaceuticals"超配"评级，目标价从65美元升至77美元
2025-09-30 14:16
